

**Tuesday 10 September, 2024 (half day – afternoon)**

**Demystifying the Science Behind Targeted Treatments and Immunotherapies for Gynaecological Cancers**

**13.00**

**Registration**

**13.30**

**Biology and genetics of cancer**

- An overview of the faulty genes, pathways, and processes that drive cancer
- The relationship between cancer and the immune system

**Targeted therapies and immunotherapies for gynae cancers**

- Introduction to targeted therapy and immunotherapy with antibodies and small molecules
- Which treatments are relevant for gynae cancers?

**14.10**

**Short break**

**14.20**

**Treating ovarian cancer with PARP inhibitors**

- What are BRCA proteins and homologous recombination?
- What have they to do with PARP inhibitors?
- Are all PARP inhibitors the same?
- Who benefits from PARP inhibitors?
- How do we test for homologous recombination deficiency (and would we want to)?

**15.00**

**Coffee break**

**15.20**

**Immunotherapy with checkpoint inhibitors**

- Checkpoint inhibitors for mismatch repair deficient and other highly mutated endometrial cancers
- Checkpoint inhibitors for cervical, vulval and vaginal cancers
- Can we use immunotherapy to treat ovarian cancer?

**15.50**

**Short break**

**16.00**

**Angiogenesis inhibitors and antibody-drug conjugates**

- Overview of angiogenesis inhibitors & experience from trials
- Introducing antibody-drug conjugates
- Mirvetuximab soravtansine for ovarian cancer
- Tisotumab vedotin for cervical cancer
- Trastuzumab deruxtecan for HER2-expressing gynae cancers

**16.30**

**Close**